Wiley Blackwell

SHERPA: Unknown

People

  1. Scher
    Scher
  2. Morris
    Morris
  3. Slovin
    Slovin
  4. Herr
    Herr
  5. Bajorin
    Bajorin
  6. Bosl
    Bosl
  7. Rathkopf
    Rathkopf
  8. Schwartz
    Schwartz
  9. Heller
    Heller
  10. Reuter
    Reuter

Groups

  1. Department of Medicine (46)
  2. Genitourinary Oncology Service (46)
  3. Solid Tumor Oncology Division (46)
  4. Hematologic Malignancies, Division of (11)
  5. Surgery (11)
  6. Urology (11)
  7. Radiology, Department of (10)
  8. GSK Faculty (8)
  9. Survivorship Research (7)
  10. Molecular Pharmacology and Chemistry Program Faculty (6)
Search Within
  1. "Howard Scher"
Formats
  1. Journal Article (39)
  2. Meeting Abstract (5)
  3. Editorial (1)
  4. Guidelines (1)
Groups
  1. Department of Medicine (46)
  2. Genitourinary Oncology Service (46)
  3. Solid Tumor Oncology Division (46)
  4. Hematologic Malignancies, Division of (11)
  5. Surgery (11)
  6. Urology (11)

More Groups

People
  1. Howard Scher (46)
  2. Michael Morris (9)
  3. Susan Slovin (9)
  4. Harry Herr (6)
  5. Dean Bajorin (5)
  6. Tracy Smart-Curley (5)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2017 (4)
  4. 2015 (4)
  5. 2014 (1)
  6. 2013 (1)

More Years

Publications
  1. Cancer (32)
  2. BJU International (6)
  3. Asia-Pacific Journal of Clinical Oncology (2)
  4. CTS-Clinical and Translational Science (2)
  5. Angewandte Chemie - International Edition (1)
  6. British Journal of Urology (1)

More Publications

Results (46)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Recommended clinical context and patient context data elements for liquid biopsy data submitted to data repositories and data commons
    Guidelines

    Grossman, R. L.; Vinson, J.; Bain, E.; Bisselou, K.; Chandan, S.; Compton, C.; Hu, J.; Johann, D. J.; Jones, F.; Jones, G.; more...
    CTS-Clinical and Translational Science (2025)

    Fulltext@MSK | Save
  • BLOODPAC: Collaborating to chart a path towards blood-based screening for early cancer detection
    Editorial

    Clarke, C. A.; Lang, K.; Putcha, G.; Beer, J. P.; Champagne, M.; Ferris, A.; Godsey, J. H.; Grossman, R. L.; Hoyos, J. M.; Johann, D. J.; more...
    CTS-Clinical and Translational Science (2023)

    Fulltext@MSK | Save
  • Trial of rucaparib in prostate indications 2 (TRITON2): An international, multicentre, open-label phase 2 study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Meeting Abstract

    Shapiro, J.; Voskoboynik, M.; Krieger, L.; Byard, I.; Clay, T.; Ganju, V.; Abida, W.; Chowdhury, S.; Watkins, S.; Despain, D.; more...
    Asia-Pacific Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Meeting Abstract

    Krieger, L.; Shapiro, J.; Byard, I.; Campbell, D.; Clay, T.; Ganju, V.; Watkins, S.; Simmons, A.; Go, J.; Shetty, S.; more...
    Asia-Pacific Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel
    Journal Article

    Armstrong, A. J.; Saad, F.; Phung, D.; Dmuchowski, C.; Shore, N. D.; Fizazi, K.; Hirmand, M.; Forer, D.; Scher, H. I.; De Bono, J.
    Cancer (2017)

    Fulltext@MSK | Save
  • Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial
    Journal Article

    Loriot, Y.; Fizazi, K.; de Bono, J. S.; Forer, D.; Hirmand, M.; Scher, H. I.
    Cancer (2017)

    Fulltext@MSK | Save
  • Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications
    Journal Article

    Rathkopf, D. E.; Larson, S. M.; Anand, A.; Morris, M. J.; Slovin, S. F.; Shaffer, D. R.; Heller, G.; Carver, B.; Rosen, N.; Scher, H. I.
    Cancer (2015)

    Fulltext@MSK | Save
  • Long-term (LT) Exposure to low-dose prednisone given with or without abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients
    Meeting Abstract

    Ryan, C. J.; Chi, K. N.; de Bono, J. S.; Fizazi, K.; Gomella, L. G.; Miller, K.; Rathkopf, D. E.; Scher, H. I.; Shore, N. D.; De Porre, P.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • Development of novel metastatic prostate cancer cell lines by 'organoid' in vitro culture technology
    Meeting Abstract

    Vela, I.; Gao, D.; Gopalan, A.; Sboner, A.; Undvall, E.; Wanjala, J.; Iaquinta, P.; Wongvipat, J.; Dowling, C.; Karthaus, W.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • Enzalutamide in European and North American men participating in the AFFIRM trial
    Journal Article

    Merseburger, A. S.; Scher, H. I.; Bellmunt, J.; Miller, K.; Mulders, P. F. A.; Stenzl, A.; Sternberg, C. N.; Fizazi, K.; Hirmand, M.; Franks, B.; more...
    BJU International (2015)

    Fulltext@MSK | Save